A clinical trial of intravenous bleomycin in the treatment of brain tumors.
The author has carried out the administration of bleomycin, chiefly by the intravenous route, in the postoperative adjuvant treatment of 150 cases of brain tumor since January 1969. The overall response rate of gliomas to bleomycin was more than 50 per cent. No distinct, given tendency toward possible differences in bleomycin effectiveness due to the type and location of tumors was revealed, but it appears that there were fewer effective cases among highly malignant gliomas and metastitic brain tumors. The survival data also showed encouraging results.
D000293:Adolescent; D000328:Adult; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002277:Carcinoma / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D007278:Injections, Spinal; D008297:Male; D008579:Meningioma / Q000188:drug therapy; D009362:Neoplasm Metastasis; D011182:Postoperative Care
D001761:Bleomycin